

Published November 2017

SIGN 154: Pharmacological management of glycaemic control in people with type 2 diabetes

Review report

Date	Update request	Decision	Status	Description
May 2022	Scoping for update	Agreed	Pending (added to SIGN Work programme)	The 3-year scoping was considered and approved for update by the Healthcare Improvement Scotland Work Programme Committee. This was deferred from 2020 when SIGN paused routine work to support Scottish Government priorities during the COVID-19 pandemic.
March 2024	The Scottish Medicines Consortium advised SIGN of the discontinuation of exenatide (Byetta®), 5 micrograms & 10 micrograms, solution for injection, prefilled pen.	Agreed	Update published April 2024	Section 9 - introduction Updated introduction to section 9 on glucagon-like peptide-1 receptor agonists to reflect availability and discontinuation of drugs in this class.